| 22 Aug 2026, 00:24 | Application for quotation of securities - ATH | Other | — | 06020 |
| 18 Aug 2026, 00:52 | Disclosure Under Takeovers Panel GN 20 | Company Administration | — | 06009, 12008 |
| 15 Aug 2026, 02:08 | Application for quotation of securities - ATH | Other | — | 06020 |
| 12 Aug 2026, 18:36 | Granted New U.S. Composition of Matter Patent for ATH434 | Company Update | MS | 11001 |
| 11 Aug 2026, 04:01 | Application for quotation of securities - ATH | Other | — | 06020 |
| 6 Aug 2026, 20:05 | Alterity to Present at Canaccord Genuity Growth Conference | Company Administration | — | 12008 |
| 4 Aug 2026, 02:22 | Application for quotation of securities - ATH | Other | — | 06020 |
| 30 July 2026, 20:00 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 |
| 29 July 2026, 19:01 | Upcoming Expiry of ATHO Listed Options | Letters & Addresses | — | 06009, 16001 |
| 28 July 2026, 20:57 | Application for quotation of securities - ATH | Other | — | 06020 |
| 22 July 2026, 03:02 | Alterity to Participate in the BTIG Biotechnology Conference | Company Administration | — | 12008 |
| 21 July 2026, 23:00 | Application for quotation of securities - ATH | Other | — | 06020 |
| 10 July 2026, 01:52 | ATH Receives A$3.98m R&D Tax Incentive | Periodic Reports | MS | 03014 |
| 9 July 2026, 21:40 | Application for quotation of securities - ATH | Other | — | 06020 |
| 7 July 2026, 19:44 | FDA Meeting Minutes Confirm Registrational Path for ATH434 | Company Update | MS | 11001 |
| 2 July 2026, 02:51 | Application for quotation of securities - ATH | Other | — | 06020 |
| 30 June 2026, 18:16 | Change in substantial holding | Substantial Holders | — | 02002 |
| 17 June 2026, 21:54 | Change of Director's Interest Notice x 2 | Director Interests | — | 02009 |
| 16 June 2026, 20:40 | Corporate Presentation June 2026 | Presentations | — | 03026 |
| 16 June 2026, 00:41 | Notification regarding unquoted securities - ATH | Other | — | 06021 |
| 16 June 2026, 00:32 | Notification of cessation of securities - ATH | Other | — | 06027 |
| 13 June 2026, 00:52 | Completion of Consolidation | Securities Administration | — | 06005, 06009 |
| 9 June 2026, 19:01 | Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA | Company Update | MS | 11001 |
| 4 June 2026, 19:49 | Share Consolidation Effective, Trading Under ATHDA | Company Administration | — | 06005, 12008 |
| 4 June 2026, 02:59 | Change of Registered Office Address | Securities Administration | — | 12003 |
| 29 May 2026, 23:59 | Results of Meeting | Meetings & Governance | — | 08003 |
| 19 May 2026, 20:02 | Alterity Data Supports ATH434 Phase 3 Advancement in MSA | Company Update | — | 11001 |
| 12 May 2026, 22:22 | Corporate Presentation May 2026 | Presentations | — | 03026 |
| 11 May 2026, 19:25 | Alterity Announces Publication on MRI as Biomarker for MSA | Company Update | — | 11001 |
| 7 May 2026, 21:35 | Alterity to Deliver Presentations at May Medical Meetings | Company Administration | — | 12008 |
| 30 Apr 2026, 21:45 | Consolidation/Split - ATH | Securities Administration | — | 06005, 06007 |
| 30 Apr 2026, 19:53 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 |
| 29 Apr 2026, 22:54 | Notice of General Meeting/Proxy Form | Presentations | MS | 06005, 08004, 08007, 14014, 16002 |
| 27 Apr 2026, 18:56 | Alterity Receives Positive FDA Feedback on CMC Meeting | Company Update | MS | 11001 |
| 24 Apr 2026, 18:14 | Change in substantial holding | Substantial Holders | — | 02002 |
| 22 Apr 2026, 19:57 | Alterity Presents New Analysis of ATH434 Phase 2 Data at AAN | Company Update | — | 11001 |
| 21 Apr 2026, 20:40 | Initial Director's Interest Notice - Cunningham | Director Interests | — | 02008 |
| 21 Apr 2026, 05:06 | Notification regarding unquoted securities - ATH | Other | — | 06021 |
| 21 Apr 2026, 05:05 | Notification regarding unquoted securities - ATH | Other | — | 06021 |
| 17 Apr 2026, 19:54 | Alterity Appoints Biotech Executive Ann Cunningham to Board | Company Administration | — | 12001 |
| 16 Apr 2026, 22:35 | Alterity Announces Late-Breaker Oral Presentation at AAN | Company Administration | — | 12008 |
| 15 Apr 2026, 20:55 | Alterity to Host KOL Event to Share New Insights on ATH434 | Presentations | — | 14014 |
| 2 Apr 2026, 01:01 | Corporate Presentation April 2026 | Presentations | — | 03026 |
| 30 Mar 2026, 20:57 | Alterity Receives Positive FDA Feedback From Type C Meeting | Company Update | MS | 11001 |
| 27 Mar 2026, 05:16 | Notification regarding unquoted securities - ATH | Other | — | 06021 |
| 20 Mar 2026, 04:00 | Proposed issue of securities - ATH | Securities Administration | — | 06013 |
| 13 Mar 2026, 00:32 | Unmarketable Parcel Sale Facility | Letters & Addresses | — | 06009, 16002 |
| 9 Mar 2026, 22:40 | Alterity to Participate in the Bell Potter Healthcare Summit | Company Administration | — | 12008 |
| 4 Mar 2026, 20:31 | Dr Daniel Claassen as Chief Medical Advisor | Company Administration | — | 12008 |
| 26 Feb 2026, 20:19 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 |